Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in type 2 diabetes mellitus with hyperuricemia
ChiCTR1900021231Phase 4Not yet recruiting
- Sponsor
- Beijing Luhe Hospital
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of canagliflozin in type 2 diabetes mellitus (T2DM) and hyperuricemia, sponsored by Beijing Luhe Hospital. Primary endpoints: Serum uric acid and Glycosylated hemoglobin. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hyperuricemia
Beyond the preview
Go deeper on ChiCTR1900021231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021231.